BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2821790)

  • 1. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme.
    Jackson D; Kinsella T; Rowland J; Wright D; Katz D; Main D; Collins J; Kornblith P; Glatstein E
    Am J Clin Oncol; 1987 Oct; 10(5):437-43. PubMed ID: 2821790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: a comparison of short versus long intravenous dose schedules (RTOG 86-12).
    Urtasun RC; Cosmatos D; DelRowe J; Kinsella TJ; Lester S; Wasserman T; Fulton DS
    Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):207-14. PubMed ID: 8407393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation.
    Goffman TE; Dachowski LJ; Bobo H; Oldfield EH; Steinberg SM; Cook J; Mitchell JB; Katz D; Smith R; Glatstein E
    J Clin Oncol; 1992 Feb; 10(2):264-8. PubMed ID: 1310102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma.
    Sullivan FJ; Herscher LL; Cook JA; Smith J; Steinberg SM; Epstein AH; Oldfield EH; Goffman TE; Kinsella TJ; Mitchell JB
    Int J Radiat Oncol Biol Phys; 1994 Oct; 30(3):583-90. PubMed ID: 7928489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-arterial bromodeoxyuridine radiosensitization of malignant gliomas.
    Hegarty TJ; Thornton AF; Diaz RF; Chandler WF; Ensminger WD; Junck L; Page MA; Gebarski SS; Hood TW; Stetson PL
    Int J Radiat Oncol Biol Phys; 1990 Aug; 19(2):421-8. PubMed ID: 2168357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers.
    Kinsella TJ; Mitchell JB; Russo A; Morstyn G; Glatstein E
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1399-406. PubMed ID: 6381432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
    Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
    Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme.
    Kinsella TJ; Collins J; Rowland J; Klecker R; Wright D; Katz D; Steinberg SM; Glastein E
    J Clin Oncol; 1988 May; 6(5):871-9. PubMed ID: 2835444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study.
    Phillips TL; Levin VA; Ahn DK; Gutin PH; Davis RL; Wilson CB; Prados MD; Wara WM; Flam MS
    Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):709-14. PubMed ID: 1651306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: final report of RTOG 86-12, Phase I-II study.
    Urtasun RC; Kinsella TJ; Farnan N; DelRowe JD; Lester SG; Fulton DS
    Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1163-7. PubMed ID: 8985039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.
    Chang EL; Loeffler JS; Riese NE; Wen PY; Alexander E; Black PM; Coleman CN
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):65-70. PubMed ID: 9422559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.
    Levin VA; Prados MR; Wara WM; Davis RL; Gutin PH; Phillips TL; Lamborn K; Wilson CB
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):75-83. PubMed ID: 7721642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer.
    Kinsella TJ; Russo A; Mitchell JB; Collins JM; Rowland J; Wright D; Glatstein E
    Int J Radiat Oncol Biol Phys; 1985 Nov; 11(11):1941-6. PubMed ID: 2997090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical rationale for S-phase radiosensitization in human tumors.
    McGinn CJ; Kinsella TJ
    Curr Probl Cancer; 1993; 17(5):273-321. PubMed ID: 8281809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.
    Schulz CA; Mehta MP; Badie B; McGinn CJ; Robins HI; Hayes L; Chappell R; Volkman J; Binger K; Arzoomanian R; Simon K; Alberti D; Feierabend C; Tutsch KD; Kunugi KA; Wilding G; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1107-15. PubMed ID: 15234045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Halogenated pyrimidines as radiosensitizers for high grade glioma: revisited.
    Rodriguez R; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):859-62; discussion 865. PubMed ID: 1651310
    [No Abstract]   [Full Text] [Related]  

  • 17. A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation.
    Kinsella TJ; Russo A; Mitchell JB; Rowland J; Jenkins J; Schwade J; Myers CE; Collins JM; Speyer J; Kornblith P
    Int J Radiat Oncol Biol Phys; 1984 Jan; 10(1):69-76. PubMed ID: 6321412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
    Prados MD; Seiferheld W; Sandler HM; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1147-52. PubMed ID: 15001257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.
    Groves MD; Maor MH; Meyers C; Kyritsis AP; Jaeckle KA; Yung WK; Sawaya RE; Hess K; Bruner JM; Peterson P; Levin VA
    Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):127-35. PubMed ID: 10477016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-arterial bromodeoxyuridine radiosensitization and radiation in treatment of malignant astrocytomas.
    Greenberg HS; Chandler WF; Diaz RF; Ensminger WD; Junck L; Page MA; Gebarski SS; McKeever P; Hood TW; Stetson PL
    J Neurosurg; 1988 Oct; 69(4):500-5. PubMed ID: 3047341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.